by American Society of Gene & Cell Therapy
<p>The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.</p>
Language
🇺🇲
Publishing Since
10/12/2022
Email Addresses
1 available
Phone Numbers
0 available
April 14, 2025
<p>On this episode of The Issue, Host Emily Walsh Martin, PhD, is tackling her absolute favorite subject: the importance of long-term data!</p> <p>Emily is joined by Dolan Sondhi, PhD, of Weill Cornell Medical College, to discuss her recent paper, “Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease.”</p> <p>We hope to see all of your long-term data at the ASGCT Annual Meeting, the premier event in cell and gene therapy, next month! Join us in New Orleans May 13-17, where we'll learn from more than 2,100 abstracts submitted for presentation. For information about the program, registration, and more, visit: <a href="https://annualmeeting.asgct.org/">https://annualmeeting.asgct.org/</a>. </p> <p><strong>Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0" data-cke-saved-href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a><br>--------------------------<br>Bright New Morning - Steven O'Brien</strong></p> <p><strong>(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt" data-cke-saved-href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)</strong></p><p><a href="https://asgct.org/membership/donate" rel="payment">Show your support for ASGCT!: https://asgct.org/membership/donate</a></p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
March 11, 2025
<p>Today, Niki Gallo, principal consultant of regulatory affairs at Halloran Consulting, joins host Emily Walsh Martin for a deep dive into timeline management pitfalls, the nuances of INDs, and the rapidly evolving FDA landscape. Niki brings to the program her extensive experience shepherding innovative therapeutics through the regulatory process and timely insights into the complexities of transitioning from the bench to the bedside.</p> <p>Whether you’re from industry or academia, today’s conversation will help wrap all our heads around testing novel therapies for the first time in humans.</p> <p>The ASGCT Annual Meeting is almost here! Join us in New Orleans May 13-17 for the premier event in CGT and save $465 by joining ASGCT and using the incredible discounts the Society provides to members. Visit <a href="annualmeeting.asgct.org">annualmeeting.asgct.org</a> to check out the full program, plan your trip, and register for the ASGCT Annual Meeting.</p> <p><strong>Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a><br>--------------------------<br>Bright New Morning - Steven O'Brien</strong></p> <p><strong>(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)</strong></p><p><a href="https://asgct.org/membership/donate" rel="payment">Show your support for ASGCT!: https://asgct.org/membership/donate</a></p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
March 4, 2025
<p>Drs. Ayşegül Yildiz and Tim Beissert join Dr. Paloma Giangrande to discuss a recent article published in Molecular Therapy Nucleic Acids by Drs. Yildiz. Beissert, and colleagues titled “Trans-amplifying RNA expressing functional miRNA mediates target gene suppression and simultaneous transgene expression”.</p> <p>Are you registered for ASGCT’s 2025 Annual Meeting in New Orleans? Join us May 13-17 for the premier event in our field and save $465 as an ASGCT member. Check out the full program, plan your trip, and register for the ASGCT Annual Meeting by visiting <a href="annualmeeting.asgct.org">annualmeeting.asgct.org</a>.</p> <p><strong>In This Episode</strong></p> <p>Paloma Giangrande, PhD<br>Editor-in-chief of Molecular Therapy Nucleic Acids<br>Senior Vice President Discovery & Translational Biology, Orbital Therapeutics</p> <p>Ayşegül Yildiz, PhD<br>Scientist of TRON’s Cardiovascular Therapeutics Group</p> <p>Tim Beissert, PhD<br>Senior Scientist and Group Leader of TRON’s Vector Development and Gene Transfer Team</p><p><a href="https://asgct.org/membership/donate" rel="payment">Show your support for ASGCT!: https://asgct.org/membership/donate</a></p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
Matt Pillar
Erin Harris
STAT
The New York Times
Andreessen Horowitz, a16z Bio + Health
NPR
The Wall Street Journal & Gimlet
NPR
New York Times Opinion
Springer Nature Limited
The New York Times
TED
Science Magazine
WBUR
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.